NASDAQ, STEM - Stemcells Inc

StemCells, Inc. is engaged in the discovery and development of cell-based  therapeutics to treat damage to, or degeneration of, major organ systems. Our  aim is to restore or support organ function, improve patients? lives and reduce  the substantial health care costs associated with these diseases and disorders  by identifying and developing stem and progenitor cells as potential therapeutic  agents. We currently have product development programs for two cell types: the  human neural stem cell and human liver engrafting cells. In our CNS Program, we  are conducting a Phase I clinical trial to evaluate the safety and preliminary  efficacy of our HuCNS-SC? product candidate (purified human neural stem cells)  as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis  (NCL), two forms of a group of disorders often referred to as Batten disease. We  have completed enrollment and dosing in this six-patient trial and expect it to  be completed in early 2009.  ...

Sector:	Health Care
Industry:	Biotechnology: Biological Products (No Diagnostic Substances)
P/E Ratio:	N/A
PEG Ratio:	N/A
EPS:	N/A
DivYield:	N/A
PtB:	N/A
PtS:	N/A
EBITDA:	N/A
Shares:	N/A
Market Cap:	N/A
52wk range:	0.33 - 6.00

216.73.216.229
United States